Olivér M. Balogh

Olivér M. Balogh

Auto-generated profile, based on publicly available information

Olivér M. Balogh

Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXu-Wen Wang
Xu-Wen Wang
LMLorenzo Madeddu
Lorenzo Madeddu
KSKerstin Spirohn
Kerstin Spirohn
LMLeonardo Martini
Leonardo Martini
AFAdriano Fazzone
Adriano Fazzone
YLYang-Yu Liu
Yang-Yu Liu
Comprehensive understanding of the human protein-protein interaction (PPI) network, aka the human interactome, can provide important insights into the molecular mechanisms of complex biological processes and diseases. Despite the remarkable experimental efforts undertaken to date to determine the structure of the human interactome, many PPIs remain unmapped. Computational approaches, especially network-based methods, can facilitate the identification of previously uncharacterized PPIs. Many such methods have been proposed. Yet, a systematic evaluation of existing network-based methods in predicting PPIs is still lacking. Here, we report community efforts initiated by the International Network Medicine Consortium to benchmark the ability of 26 representative network-based methods to predict PPIs across six different interactomes of four different organisms: A. thaliana, C. elegans, S. cerevisiae, and H. sapiens. Through extensive computational and experimental validations, we found that advanced similarity-based methods, which leverage the underlying network characteristics of PPIs, show superior performance over other general link prediction methods in the interactomes we considered.

7 February 2025 in Drug Safety
Verified
Journal Article
Open access
PDF file
Maria Antonietta BarbieriMaria Antonietta Barbieri
Maria Antonietta Barbieri
AAAndrea Abate
Andrea Abate
OBOlivér M. Balogh
Olivér M. Balogh
MPMátyás Pétervári
Mátyás Pétervári
PFPéter Ferdinandy
Péter Ferdinandy
MSMaurizio Sessa
Maurizio Sessa
Background Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic health records (EHRs) and administrative databases are leveraged for signal detection. Although network analysis has shown promise in mapping relationships between clinical attributes for signal detection in spontaneous reporting system databases, its application in real-world data from EHRs and administrative databases remains limited. Objective This study aimed to evaluate the performance of network analysis in detecting safety signals within Italian administrative databases, using drug-induced acute myocardial infarction (AMI) as a proof of concept. Methods We employed a case–crossover design to explore the association between drug exposure and AMI using the Healthcare Administrative Database of Mantova, Italy, from 2014 to 2018. Patients with their first AMI hospitalization were identified after a 365-day washout period to exclude prior hospitalizations. We constructed a network to analyse the relationships between prescribed drugs and diagnoses, represented as nodes, with undirected edges illustrating their interactions. For each patient with AMI, we identified all diagnoses and drugs recorded or redeemed within 365 days of the first AMI episode and generated various drug–diagnosis, drug–drug, and diagnosis–diagnosis pairs. We calculated the frequency of these pairs, and three types of edge weights quantified the strength of connections. We identified outlier drug–AMI pairs using a predictive score (F) based on frequency (C) and full edge weights (WF), with validation for known AMI associations. We prioritized signals using the F score, C of AMI, and WF, analysed through k-means clustering to identify patterns in the data. Results From 2014 to 2018, a total of 3918 patients had an AMI, with 4686 AMI diagnoses. Of those, 2866 had prescriptions in the previous year, totalling 498,591 prescriptions. A network analysis identified 2968 unique nodes, revealing 529,935 diagnosis–diagnosis connections, 235,380 drug–diagnosis connections, and 102,831 drug–drug connections. The median number of connections (C) was 404 (Q1–Q3: 194–671) for drug nodes and 380 (Q1–Q3: 216–664) for diagnosis nodes. The median WF was 11.8 (Q1–Q3: 9–14), and the median F score across pairs was 0.1 (Q1–Q3: 0.1–0.3). A total of 249 potential safety signals were detected, with 63.4% aligning with known AEs. Among the remaining signals, 80 were prioritized, and five emerged as the highest priority: terazosin, tamsulosin, allopurinol, esomeprazole, and omeprazole. Conclusions Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases.

8 June 2025 in bioRxiv
Verified
Preprint
Open access
OBOlivér M Balogh
Olivér M Balogh
MPMátyás Pétervári
Mátyás Pétervári
ÁCÁron M Csernák
Áron M Csernák
EPEszter Puhl
Eszter Puhl
Andras HorvathAndras Horvath
Andras Horvath
BABence Agg
Bence Agg
Post-marketing surveillance is crucial for drug safety, yet the tools of pharmacovigilance rely solely on text-based data that may limit the applicability of contemporary machine learning methodologies in the support of decision making. Here, we adapt contrastive learning algorithms to generate adverse event vector representations from spontaneous reports to serve as general machine-readable resources for pharmacovigilance applications. We present comprehensive analyses of the resulting representations through density-based clustering, semantic evaluation and comparison of multivariate dispersions, revealing patterns that reflect both functional and causal relations of the adverse events while also capturing drug-safety related information better than existing medical terminologies and encoder-only large language models (LLMs). Furthermore, we demonstrate the applicability of the representations as input features in our downstream model, outperforming the reporting odds ratio method commonly used by regulatory agencies (AUROC: 0.88 vs 0.75) and LLM-based representations (AUROC: 0.88 vs 0.83) on drug–event causality prediction benchmarks. As such, this is the first demonstration of an interpretable adverse event vector representation that can be utilized for training arbitrary models, enabling wider and more effective applications of machine learning in pharmacovigilance.